Esketamine and FDA approvals

With the success of ketamine therapy used intravenously seen across the nation, the creation of an FDA approved treatment was inevitable. In 2019 a nasal spray, esketamine, also known as Spravato, was approved for the treatment of Treatment-Resistant Depression.

With the addition of this new medication, patients across the nation now have the option to utilize ketamine or esketamine treatments for their depression.